Previous studies have demonstrated that nuclear factor kappa B (NF­-κB) functions in many cellular constituents of the tumor microenvironment and modulates inflammation, tumorigenesis, and metastasis; therefore, we first hypothesized that triple therapy might play a role in blocking NF­-κB activation. Here, NFKB1 is linked to neoplasm.